ArticleESC heart failure2021

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.

Moritz J Hundertmark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.